Efficacy of Pritelivir and Acyclovir in the Treatment of Herpes Simplex Virus Infections in a Mouse Model of Herpes Simplex Encephalitis

Pritelivir, a helicase-primase inhibitor, has excellent in vitro and in vivo activity against human herpes simplex virus (HSV). Mice lethally infected with HSV type 1 or 2, including acyclovir-resistant strains, were treated 72 hours after infection for 7 days with pritelivir or acyclovir. Both drug...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Antiviral Res
Main Authors: Quenelle, Debra C., Birkmann, Alexander, Goldner, Thomas, Pfaff, Tamara, Zimmermann, Holger, Bonsmann, Susanne, Collins, Deborah J., Rice, Terri L., Prichard, Mark N.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5743594/
https://ncbi.nlm.nih.gov/pubmed/29113740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2017.11.002
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki